Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2014

View Archived Issues

Scientists develop paper-based, cell-free, stable, synthetic gene network arrays

Genmab confirms phase II study of daratumumab in non-Hodgkin's lymphomas

NeuroSolis presents novel M1/M4-selective agonists for Alzheimer's disease

Characterization of a potent and selective PDE10A inhibitor, RO-5461861

Idenix presents phase I/II data for MK-3682 in patients with HCV infection

Acetylon initiates phase II multiple myeloma study of ricolinostat in combination with Pomalyst

ProMetic to evaluate PBI-4050 in new indication

Phase III data presented from the MOBILITY trial evaluating sarilumab in patients with RA

NCI contracts MRIGlobal to develop HPV vaccine

EMA determines no evidence that Fluad caused deaths in Italy

CCX-168 receives European orphan designation for ANCA-associated vasculitis

Pluristem collaborates with Hadassah Medical Center on PLX-RAD

Sichuan Haisco Pharmaceutical patents novel SGLT2 inhibitors

Kalvista Pharmaceuticals reports selective plasma kallikrein inhibitors

Phase I data for the Notch signaling inhibitor BMS-906024 in patients with T-ALL and T-LL

Alnylam files application to conduct U.K. trial of ALN-CC5 in PNH

Basilea re-introduces antibiotic ceftobiprole medocaril

BTG to acquire PneumRx

Takeda launches global oncology business unit Takeda Oncology

Sunovion files sNDA for Aptiom as monotherapy for partial-onset seizures

FDA committee votes on Actavis' NDA for ceftazidime/avibactam

Lutinus for luteal supplementation launched in Japan

Daiichi Sankyo launches Lixiana in Japan for new indications

FDA approves Xgeva for hypercalcemia of malignancy

European approval for Moventig for opioid-induced constipation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...